Drugs / HLX-1502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06541847 | Feb 2025 → Jun 2027 expected | neurofibromatosis type 1 | Healx Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-10-28 | Healx AI | Regulatory U.S. FDA Grants Fast Track designation for HLX-1502 in Neurofibromatosis Type 1 (NF1) Treatment healx.ai ↗
We are proud to announce a significant milestone for Healx: our lead program asset, HLX-1502, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of neurofibromatosis type 1 (NF1). |
| 2024-08-01 | Healx AI | Regulatory Healx Announces $47 million Series C Financing and FDA Clearance of Phase 2 IND for Neurofibromatosis Type 1 Trial healx.ai ↗
U.S. FDA has cleared its investigational new drug (IND) application to advance HLX-1502 in Phase 2 clinical trial in NF1; |
| 2023-09-06 | Healx AI | Regulatory Healx receives US Orphan Drug Designation for its AI-discovered treatment of Neurofibromatosis Type 1 (NF1) healx.ai ↗ |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX-1502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06541847 ↗ |
| Route | Oral | “Participants will take an oral dose three times a day” NCT06541847 ↗ |